Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Amosartan Q vs Co-administration of Amosartan and Rosuvastatin
NCT04039724Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2015
- Primary completion
- May 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Amosartan Q in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Feb 2015; status: completed.
02
Drugs
Amosartan Q
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04039724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039724.